BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33730659)

  • 21. Prediction of
    Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioma grading and IDH1 mutational status: assessment by intravoxel incoherent motion MRI.
    Wang X; Chen XZ; Shi L; Dai JP
    Clin Radiol; 2019 Aug; 74(8):651.e7-651.e14. PubMed ID: 31014573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
    Liu Z; Zhang T; Jiang H; Xu W; Zhang J
    Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological tumour volumes of gliomas in early and standard 20-40 min
    Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
    Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
    AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
    Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Volumetric Analysis of Extent of Resection, Survival, and Surgical Outcomes for Insular Gliomas.
    Eseonu CI; ReFaey K; Garcia O; Raghuraman G; Quinones-Hinojosa A
    World Neurosurg; 2017 Jul; 103():265-274. PubMed ID: 28408263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectral Analysis Based on Hemodynamic Habitat Imaging Predicts Isocitrate Dehydrogenase Status and Prognosis in High-Grade Glioma.
    Qiao J; Wu H; Liu J; Kang H; Wang S; Fang J; Zhang J; Zhang W
    World Neurosurg; 2023 Jul; 175():e520-e530. PubMed ID: 37028478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
    Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
    Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors.
    Riva M; Lopci E; Castellano A; Olivari L; Gallucci M; Pessina F; Fernandes B; Simonelli M; Navarria P; Grimaldi M; Rudà R; Castello A; Rossi M; Alfiero T; Soffietti R; Chiti A; Bello L
    World Neurosurg; 2019 Jun; 126():e270-e280. PubMed ID: 30797926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative texture analysis in the prediction of IDH status in low-grade gliomas.
    Jakola AS; Zhang YH; Skjulsvik AJ; Solheim O; Bø HK; Berntsen EM; Reinertsen I; Gulati S; Förander P; Brismar TB
    Clin Neurol Neurosurg; 2018 Jan; 164():114-120. PubMed ID: 29220731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of APT imaging in gliomas grading: A systematic review and meta-analysis.
    Sotirios B; Demetriou E; Topriceanu CC; Zakrzewska Z
    Eur J Radiol; 2020 Dec; 133():109353. PubMed ID: 33120241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
    Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
    J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ki-67 labeling index and the grading of cerebral gliomas by using intravoxel incoherent motion diffusion-weighted imaging and three-dimensional arterial spin labeling magnetic resonance imaging.
    Wang C; Dong H
    Acta Radiol; 2020 Aug; 61(8):1057-1063. PubMed ID: 31830431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of intraoperative ultrasound characteristics with pathological grades and Ki-67 proliferation index in intracranial gliomas.
    Baskan O; Silav G; Sari R; Canoz O; Elmaci I
    J Med Ultrason (2001); 2015 Apr; 42(2):231-7. PubMed ID: 26576577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.